Abstract: The present invention relates to new antifungal compounds having the formula ##STR1## wherein R.sup.1 is hydrogen, methyl, or hydroxymethyl; R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen and C.sub.1-5 alkyl; and R.sup.4 is selected from the group consisting of .beta.-L-xylosyl, .beta.-D-ribosyl, .alpha.-L-arabinosyl, .beta.-D-chinovosyl, .beta.-D-fucosyl, and .beta.-D-glucosyl; with the proviso that when R.sup.1 is methyl or hydroxymethyl, and one of R.sup.2 or R.sup.3 is methyl, R.sup.4 is not .beta.-D-glucosyl; or a pharmaceutically acceptable salt thereof.

Abstract: This invention relates to novel elsamicin A derivatives wherein the 2"-amino group is selectively modified by acylation or alkylation, a process for producing said elsamicin A derivatives, an antitumor composition containing the same as the active ingredient, and a method for therapy using said compositions.

Abstract: This invention relates to elsamicin A derivatives wherein the 2"-amino group is selectively modified by acylation or alkylation, a process for producing said elsamicin A derivatives, an antitumor composition containing the same as the active ingredient, and a method for therapy using said compositions.

Abstract: This invention relates to novel elsamicin A derivatives having an alkylidene group on the 3' and 4'-OH group or a tetrahydropyranyl group on the 4'-OH group, a process for producing said elsamicin A derivatives, antitumor composition containing the same as the active ingredient, and a method for therapy using said compositions.

Abstract: 7-[2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(substituted)-iminoacetamido]-3-[3-( quaternaryammonio)-1-propen-1-yl]-3-cephem-4-carboxylates of the formula ##STR1## in which R.sup.1 and R.sup.2 are defined herein and --.sup..sym. N.tbd.Q is a quaternary ammonio group as defined herein, and salts, solvates, hydrates and esters thereof, are potent antibacterial agents. Processes for their preparation and intermediates in such processes are described.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is hydrogen or a conventional amino-protecting group, R.sup.2 is a straight or branched chain alkyl group containing from 1 to 4 carbon atoms, allyl, 2-butenyl, 3-butenyl, propargyl, 2-butynyl, 3-butynyl, cycloalkyl containing from 3 to 6 carbon atoms or a group of the formula ##STR2## in which R.sup.3 and R.sup.4 each are independently hydrogen, methyl or ethyl, or R.sup.3 and R.sup.4, taken together with the carbon atom to which they are attached, may be a cycloalkylidene ring containing from 3 to 6 carbon atoms or a substituted cyclobutylidene ring of the formula ##STR3## wherein X is halogen, hydroxy or (lower)alkoxy, and R.sup.5 and R.sup.

Abstract: A bronchodilating process employing purine derivatives "9-cyclohexyl-9H-adenine er 9-benzyl-2-n-propoxy-9H-adenine" is disclosed.

Abstract: Adenine derivatives with 2-alkylthio and 9-(2-cyclohexenyl or cyclohexyl) substituents having non-adrenergic bronchodilating properties and use in the treatment or prophylaxis of broncho-constriction in mammals are disclosed.

Abstract: New 2-substituted-6-amino-9-tetrahydropyran-2-yl purine derivatives are disclosed. They are orally active bronchodilators with relatively little cardiovascular side effects. A representative and preferred embodiment of this invention is 2-n-propoxy-9-(tetrahydropyran-2-yl)-9H-adenine.

Abstract: New orally active bronchodilating 6-amino-purine derivatives substituted in the two position with alkylamino or cyclohexylamino and in the nine position with 2-cyclohexenyl or cyclohexyl are disclosed.

Abstract: Purine derivatives of the formula ##STR1## wherein R is C.sub.1 -C.sub.6 alkyl and R.sub.1 is ##STR2## and their pharmaceutically acceptable acid addition salts are non-adrenergic bronchodilators.

Abstract: Purine derivatives of the formula ##STR1## wherein R is C.sub.1 -C.sub.6 alkyl and R.sub.1 is ##STR2## OR ##STR3## AND THEIR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS ARE NON-ADRENERGIC BRONCHODILATORS.